-
Aegis Sciences Corporation Launches Test for Coronavirus Disease 2019 (COVID-19)
Capacity for 3,500 tests a day begins April 15; results available within 24 hours Nashville, Tennessee (April 13, 2020) – Aegis Sciences Corporation,…
Capacity for 3,500 tests a day begins April 15; results available within 24 hours Nashville, Tennessee (April 13, 2020) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, will serve as a regional reference laboratory for COVID-19 testing being directed by Federal, State, and Local COVID-19…
-
Aegis Sciences COVID-19 Update
To Our Customers, Aegis Sciences would like to take a moment to say ‘Thank You’ to all of our partners and customers who continue to service their communities’…
To Our Customers, Aegis Sciences would like to take a moment to say ‘Thank You’ to all of our partners and customers who continue to service their communities’ healthcare needs amidst the current challenges with Coronavirus (COVID-19.) Our laboratory is and will remain fully operational and available to you as your practice continues providing essential health services in these extraordinary times. …
-
Aegis Sciences Launches New Pharmacogenetic Testing
Nashville, Tennessee (October 14, 2019) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance…
Nashville, Tennessee (October 14, 2019) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, has launched a new pharmacogenetic (PGx) test that allows for identification of specific gene variants that may impact how behavioral and pain management drugs affect patients. The test results provide…
-
We are hiring! Laboratory Open House
Aegis Sciences Corporation, a national leader in healthcare and laboratory sciences, is hiring! Thursday, September 5th, 20195:00 p.m. to 7:00 p.m. 501…
Aegis Sciences Corporation, a national leader in healthcare and laboratory sciences, is hiring! Thursday, September 5th, 20195:00 p.m. to 7:00 p.m. 501 Great Circle Road (Metro Center) | Nashville, TN Parking behind building; use back entrance. Meet with our recruiters and laboratory leaders to learn about our exciting laboratory opportunities and competitive benefits package. We are seeking…
-
Aegis now an Anthem Blue Cross and Blue Shield of Georgia participating provider
NASHVILLE, TN (June 17, 2019) - Aegis Sciences Corporation is pleased to announce that effective June 17, 2019 we will be a participating laboratory provider…
NASHVILLE, TN (June 17, 2019) - Aegis Sciences Corporation is pleased to announce that effective June 17, 2019 we will be a participating laboratory provider with Anthem Blue Cross and Blue Shield in Georgia for PPO, Medicare Advantage and Indemnity products. Our product participation with Anthem Blue Cross and Blue Shield in Georgia will allow referring physicians to utilize Aegis’ laboratory services…
-
New Research Shows How Diagnostic Testing Can Advance the Identification and Treatment of Harmful Drug-Drug Interactions
Findings of a recently published two-part study demonstrate that InterACT Rx™ can significantly enhance diagnosis and treatment of DDIs, improving patient…
Findings of a recently published two-part study demonstrate that InterACT Rx™ can significantly enhance diagnosis and treatment of DDIs, improving patient outcomes NASHVILLE, TN (December 5, 2018) - Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative testing and consulting services to providers, conducted a two-part research study to measure the performance…
-
New Research Reveals the Prevalence of Drug-Drug Interactions and the Economic Impact on the Healthcare System
Studies show an alarming prevalence of concurrent ingestion of interacting substances by patients and that providing physicians with clear, objective information…
Studies show an alarming prevalence of concurrent ingestion of interacting substances by patients and that providing physicians with clear, objective information leads to a reduction of interactions and costs for patients NASHVILLE, TN (November 5, 2018) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative testing and consulting services to providers, recently…
-
Aegis now offering definitive testing for kratom
Nashville, Tennessee (Nov. 5, 2018) - Aegis Sciences Corporation is pleased to announce definitive testing for kratom (mitragynine) via liquid chromatography-…
Nashville, Tennessee (Nov. 5, 2018) - Aegis Sciences Corporation is pleased to announce definitive testing for kratom (mitragynine) via liquid chromatography- tandem mass spectrometry (LC-MS/MS). Kratom, botanically known as Mitragyna speciosa, refers to a tropical tree found in parts of Southeast Asia belonging to the Rubiaceae family.1,2 The leaves of this tree have traditionally been used as an…
-
Aegis Study Shows Impact of InterACT Rx on Medication Management and Patient Care
Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical decision…
Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical decision making, and improve patient outcomes. Nashville, Tennessee (Oct. 9, 2018) - In a recently published study of 262 patients, there was a signifcant reduction in all-cause and painrelated outpatient visits and medication use between the pre- and…
-
Aegis study reports prevalence of identified drug-drug interactions based on detection of ingested substances.
InterACT Rx™ identified at least one drug-drug interaction (DDI) between recently ingested substances in as many as 20% of patients. Nashville, Tennessee…
InterACT Rx™ identified at least one drug-drug interaction (DDI) between recently ingested substances in as many as 20% of patients. Nashville, Tennessee (Sept. 19, 2018) - In a recently published study of more than 15,000 patients, 20% had at least one DDI identified. Risk of DDIs has been shown to contribute to patient harm, hospitalization, and increased healthcare costs. Despite improvements in…
